CN Patent

CN119405593A — 奈帕芬胺及槲皮素缓释凝胶制剂的制备方法和应用

Assigned to Shandong Qidu Pharmaceutical Co Ltd · Expires 2025-02-11 · 1y expired

What this patent protects

本发明属于药物制剂技术领域，具体涉及奈帕芬胺及槲皮素缓释凝胶制剂的制备方法和应用，所述的奈帕芬胺及槲皮素缓释凝胶制剂，包括如下质量份数的成分：奈帕芬胺，5‑75份；槲皮素，3‑60份；生物载体，100‑500份；粘度降低剂，15‑350份；非水溶剂，50‑200份。本发明不仅止痛抗炎还可促进组织修复生长，能够有效实现缓释效果，给药便捷且长效。本发明还提供其制备方法和应用。

USPTO Abstract

本发明属于药物制剂技术领域，具体涉及奈帕芬胺及槲皮素缓释凝胶制剂的制备方法和应用，所述的奈帕芬胺及槲皮素缓释凝胶制剂，包括如下质量份数的成分：奈帕芬胺，5‑75份；槲皮素，3‑60份；生物载体，100‑500份；粘度降低剂，15‑350份；非水溶剂，50‑200份。本发明不仅止痛抗炎还可促进组织修复生长，能够有效实现缓释效果，给药便捷且长效。本发明还提供其制备方法和应用。

Drugs covered by this patent

Bupivacaine Hydrochloride And Epinephrine (BUPIVACAINE) · Innocoll

Patent Metadata

Patent number: CN119405593A
Jurisdiction: CN
Classification: —
Expires: 2025-02-11
Drug substance claim: No
Drug product claim: No
Assignee: Shandong Qidu Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.